• PTC Therapeutics Executive VP and CLO Mark Elliott Boulding sold 2,812 shares on May 15, 2026 at USD 72.17, cutting his direct stake to 105,212 shares.
• The sales coincided with the exercise of stock options for 2,812 shares at USD 25.69.
• Boulding held 19,689 stock options following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001578852-26-000016), on May 19, 2026, and is solely responsible for the information contained therein.